Name of the cohort: DACHS/IMPACT

Official homepage of the study.

Basic characteristics of the study: The DACHS study (Darmkrebs: Chancen der Verhütung durch Screening) is an epidemiological population-based case-control study initiated by the German Centre for Research on Ageing (DZFA)* and the German Cancer Research Center (DKFZ) in the Rhine-Neckar-Odenwald and Heilbronn regions. Since January 2003, participants are questioned about their screening habits and lifestyle by trained interviewers in the cooperating clinics or at home. Blood samples or mouthwashes, if blood samples are not available, are obtained from all participants. Moreover,  information from medical files and tumour tissue are collected from all cases. The DACHS study was designed to contribute to the further improvement of screening programmes for colorectal cancer in the future. Patients are followed-up for up to 10 years since diagnosis of colorectal cancer.
*now based in the Division of Clinical Epidemiology and Aging Research of the German Cancer Research Center. The IMPACT research consortium (Improving long-term prognosis and quality of life of patients with colorectal cancer) is based on the DACHS-study. The primary goal is to assess the impact of clinical, life-style and genetic factors, type of medical care, social and other support and their interactions on long-term prognosis and long-term quality of life, and to identify perspectives for improving them.

Category of the cohort: Mature and Novel Patient Cohort

Kind of biomaterials available in the cohorts, i.e. data collected in the cohorts: Fresh frozen tissue (tumor, mucosa, avisceral and subcutaneous adipose and fascia tisse), FFPE of all the tissues above; presurgery blood, stool, urine, saliva. Data collection includes: Gene expression and methylation analysis in the different tissues collected, sequencing analysis of tumor DNA, miRNA analysis of tissue and blood plasma samples. Vitamin D level and VEGF in blood biospecimens. Patients are included in physical activity assessments with questionnaires and state of the art accelerometers and physical fitness tests. The volumes of different fat tissues of CRC patients are measured in representative sections of CT scans and correlated. Collagen subtype analysis related to incisional hernias will be studied on the collected fascia tissue. Blood samples are exposed to a novel proteome screen. Stool samples undergo metagenomic sequencing for a gut microbiome analysis. Metabolomics is performed in all biospecimens and 8-oxo-dG and Isoprostane levels are assessed in urine. Inflammation markers and the effect of NSAIDs on CRC outcomes are compared with tumor infiltrating lymphocytes in tumor tissue. All measures except for tissue data are performed at several timepoints during follow-up.

Application process to access the biomaterials: For the samples located in Heidelberg, please send an application for scientific collaboration to Prof. Dr. med. Hermann Brenner.

Cohorts’ data, which can be already used within iMed: Data on SNPs, tumor, mucosa and adipose tissue, gene expression,  Methylation, Metabolomics, Stool Metagenomics, miRNA and VitD in blood samples, 8-oxo-dG and Isoprostane levels are assessed in urine, clinical data, life style (nutrtion, exercise, smoking, alcohol, medication, supplements) and quality of life data.

Contact persons for the cohort: Dr. Petra Schrotz-King and Prof. Dr. med. Hermann Brenner (DKFZ Heidelberg).

to top